


## CDK12-IN-3

Cat. No.:	HY-112261		
CAS No.:	2220184-50-7		
Molecular Formula:	C <sub>23</sub> H <sub>28</sub> F <sub>2</sub> N <sub>8</sub> O		
Molecular Weight:	470.52		
Target:	CDK		
Pathway:	Cell Cycle/DNA Damage		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

In Vitro	DMSO : 250 mg/mL (531.33 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	2.1253 mL	10.6265 mL	21.2531 mL
		5 mM	0.4251 mL	2.1253 mL	4.2506 mL
10 mM		0.2125 mL	1.0627 mL	2.1253 mL	
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.33 mg/mL (4.95 mM); Clear solution				
	2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.33 mg/mL (4.95 mM); Clear solution				

### BIOLOGICAL ACTIVITY

Description	CDK12-IN-3 is a potent and selective CDK12 inhibitor with an IC <sub>50</sub> of 491 nM in enzymatic assay.
IC <sub>50</sub> & Target	CDK12 491 nM (IC <sub>50</sub> )
In Vitro	CDK12-IN-3 is a highly selective CDK12 inhibitor. CDK12-IN-3 (0.1 μM) shows potent inhibition of phosphorylation of Ser2 on the CTD repeat domain of RNA Pol II as well as growth inhibition of OV90 cells and acute cytotoxicity to THP1 cells. <sup>[1]</sup> MCE has not independently confirmed the accuracy of these methods. They are for reference only.

---

## REFERENCES

---

[1]. Johannes JW, et al. Structure-Based Design of Selective Noncovalent CDK12 Inhibitors. ChemMedChem. 2018 Feb 6;13(3):231-235.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA